Delivery Order SPE2DB25D2207-SPE2DB25FQRMW
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100 count) valued at $3,238.65. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through open procurement. The contract calls for ultimate completion by July 28, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100-count) with a ceiling value of $1,202.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for ultimate completion by August 7, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 30 mg capsules (100 count) on August 5, 2025, with a ceiling value of $2,111.70 and an ultimate completion date of August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, executed under competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 20 mg capsules (100 count) with a contract value of $1,913.34. This non-competitive, firm fixed-price delivery order was awarded on May 2, 2025, with an ultimate completion date of May 5, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,169.62 to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 10 mg capsules (100 count). The contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100 count) with a ceiling value of $1,494.30. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for ultimate completion by July 28, 2025, with performance fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,594.00 to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 20 mg capsules (100 count). The contract was competitively awarded without set-aside designation and carries an ultimate completion date of September 18, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, performed this delivery order under firm fixed price terms. This delivery order is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Dexmethylphenidate ER 20 mg capsules (100-count bottles) with a contract ceiling value of $1,772.16. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.20 to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 25 mg capsules (100 count) on August 11, 2025, with completion scheduled for August 12, 2025. This competitive, non-set-aside delivery order utilizes firm fixed price terms and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100 count) with a ceiling value of $1,606.41. This is a firm fixed-price delivery order with no set-aside designation, executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and running through December 2026. The product will be delivered to...
- SPE2DB25D2207Indefinite Delivery Contract
- SPE2DB25D2207-SPE2DB25FQRMWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100 count) with a ceiling value of $1,226.04. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 14, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this order from its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor vehicle valued at $999,999,999.00 and running through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical commodities to support military and veteran healthcare systems. Dexmethylphenidate, a controlled-release formulation of a central nervous system stimulant, is used in the treatment of attention deficit hyperactivity disorder and represents the type of specialty pharmaceutical products the company routinely delivers to the Defense Health Agency and other federal healthcare entities. All of AmerisourceBergen Drug Corp's reviewed federal contract awards with DLA have been competitively awarded without set-asides, demonstrating the company's capability to meet federal procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/13/25 |